
Fei Yang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1802932/publications.pdf Version: 2024-02-01



FEL YANG

#	Article	IF	CITATIONS
1	Effector memory cytotoxic CD3+/CD8+/CD45RO+ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer. Modern Pathology, 2022, 35, 601-608.	5.5	10
2	Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naÃ ⁻ ve gBRCA+ breast cancers. Npj Breast Cancer, 2022, 8, 64.	5.2	3
3	Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary <i>BRCA</i> Mutation. Clinical Cancer Research, 2022, 28, 3669-3676.	7.0	3
4	TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Modern Pathology, 2021, 34, 710-719.	5.5	90
5	The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Investigational New Drugs, 2021, 39, 829-835.	2.6	8
6	First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. Breast Cancer Research, 2021, 23, 29.	5.0	31
7	CD8+ T cells inhibit metastasis and CXCL4 regulates its function. British Journal of Cancer, 2021, 125, 176-189.	6.4	21
8	A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores. Breast Cancer Research and Treatment, 2021, 189, 455-461.	2.5	6
9	Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clinical Cancer Research, 2021, 27, 5365-5375.	7.0	29
10	Sphingosine Kinase 1 Signaling Promotes Metastasis of Triple-Negative Breast Cancer. Cancer Research, 2019, 79, 4211-4226.	0.9	48
11	Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. Cancers, 2019, 11, 714.	3.7	79
12	The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy. Clinical Cancer Research, 2019, 25, 4644-4655.	7.0	76
13	Atypical plant homeodomain of UBR7 functions as an H2BK120Ub ligase and breast tumor suppressor. Nature Communications, 2019, 10, 1398.	12.8	35
14	A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer, 2018, 4, 9.	5.2	32
15	Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group. Annals of Surgical Oncology, 2016, 23, 2242-2248.	1.5	85
16	Increased VEGFR-2 Gene Copy Is Associated with Chemoresistance and Shorter Survival in Patients with Non–Small-Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy. Cancer Research, 2011, 71, 5512-5521.	0.9	55